Gilead Sciences, Inc. $GILD Shares Sold by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,535 shares of the biopharmaceutical company’s stock after selling 5,656 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Gilead Sciences were worth $1,391,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in GILD. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $26,000. Howard Hughes Medical Institute purchased a new position in Gilead Sciences in the 2nd quarter valued at approximately $30,000. MTM Investment Management LLC increased its stake in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares in the last quarter. Kilter Group LLC acquired a new position in Gilead Sciences during the second quarter worth $33,000. Finally, Millstone Evans Group LLC boosted its position in Gilead Sciences by 58.7% during the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the transaction, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 309,280 shares of company stock valued at $44,068,850 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research analyst reports. Rothschild & Co Redburn raised their price target on Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. HSBC increased their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a research note on Wednesday, February 11th. Finally, Citigroup reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, March 6th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $141.11 on Friday. The firm has a 50 day simple moving average of $142.36 and a 200-day simple moving average of $127.60. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The firm has a market cap of $175.18 billion, a PE ratio of 20.84, a P/E/G ratio of 1.85 and a beta of 0.37. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.3%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.45%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Pipeline boost — Assembly Biosciences licensed a helicase‑primase inhibitor program (including candidates ABI‑5366 and ABI‑1179) to Gilead after positive Phase 1b interim data, adding early‑stage herpes assets to Gilead’s antiviral franchise and expanding near‑term development options. This is a clear pipeline + inorganic expansion signal. Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
• Positive Sentiment: Analyst support — Multiple firms have raised targets or maintain buy ratings (Deutsche Bank, Jefferies, BofA, Needham), lifting consensus target above the current trade and providing institutional buying ammunition. This helps underpin the shares despite short‑term weakness.
• Positive Sentiment: Shareholder return signal — Gilead recently raised its quarterly dividend to $0.82 (ann. $3.28), reinforcing cash‑flow confidence and appeal to income investors. Dividend / SEC Filing
• Neutral Sentiment: Trending attention / coverage — Zacks and other outlets flagged GILD as a trending stock; that can increase intraday volume and volatility but doesn’t indicate fundamental change. Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
• Neutral Sentiment: Market‑flow signals — Unusual options activity and recent coverage pieces on valuation have attracted attention; these can amplify swings but are ambiguous for direction until large trades or analyst revisions follow. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
• Negative Sentiment: Insider selling — Recent disclosed sales (including Johanna Mercier and a reported sale by the CFO) have been highlighted in filings and press summaries; insider sales can weigh on sentiment even when they’re routine or pre‑planned. Insider Sale – Johanna Mercier CFO SEC Filing

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.